New aspects of the treatment of chronic lymphocytic leukemia Stefan FaderlWilliam WierdaMichael J. Keating OriginalPaper Pages: 251 - 257
Treatment of Burkitt lymphoma in children and adults: Lessons from Africa Ian T. Magrath OriginalPaper Pages: 230 - 240
The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma Elizabeth Naparstek OriginalPaper Pages: 220 - 229
Neurologic complications of non-Hodgkin’s lymphoma Pierre GiglioMark R. Gilbert OriginalPaper Pages: 214 - 219
What signals are generated by anti-CD20 antibody therapy? Benjamin Bonavida OriginalPaper Pages: 205 - 213
The role of parenteral nutrition Nicole B. JacobsonNeha ParekhMatt Kalaycio OriginalPaper Pages: 188 - 194
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy Ryuzo Ohnothe Japan Adult Leukemia Study Group OriginalPaper Pages: 180 - 187
Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults Heather LandauNicole Lamanna OriginalPaper Pages: 171 - 179
The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era Corey CutlerJoseph H. Antin OriginalPaper Pages: 160 - 167
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction Vivian G. OehlerJerald P. Radich OriginalPaper Pages: 152 - 159
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate Jeffrey A. ZonderCharles A. Schiffer OriginalPaper Pages: 141 - 151
Gene arrays in lymphoma: Where will they fit in? Javeed IqbalFrancesco d’AmoreKai Fu OriginalPaper Pages: 129 - 136
Is cytarabine required in the treatment of acute promyelocytic leukemia? Lionel AdèsPierre Fenaux OriginalPaper Pages: 122 - 125
Clinical implications of gene expression profiling of acute myeloid leukemia Kenneth I. MillsAmanda F. Gilkes OriginalPaper Pages: 114 - 121
Chemotherapy for patients with acute myeloid leukemia in first remission Kenneth Bradstock OriginalPaper Pages: 108 - 113
Targeting the c-kit receptor in the treatment of acute myelogenous leukemia Anjali S. Advani OriginalPaper Pages: 101 - 107
Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis? Juergen ThieleHans Michael Kvasnicka OriginalPaper Pages: 87 - 92
A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2V617F Ayalew Tefferi OriginalPaper Pages: 81 - 86
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective Martha WadleighD. Gary Gilliland OriginalPaper Pages: 75 - 80
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia David DingliAyalew Tefferi OriginalPaper Pages: 69 - 74
Nodular lymphocyte-predominant Hodgkin’s lymphoma Lucia NogovàVolker Diehlthe German Hodgkin Study Group OriginalPaper Pages: 60 - 65
First-line treatment of Hodgkin’s lymphoma Beate KlimmAndreas EngertVolker Diehl OriginalPaper Pages: 51 - 59
Advances in the treatment of chronic lymphocytic leukemia Nicole Lamanna OriginalPaper Pages: 43 - 48
Initial chemotherapy for chronic lymphocytic leukemia: What’s the standard of care? Matt Kalaycio Clinical Trials Report Pages: 41 - 42
Arsenic trioxide as a treatment for myelodysplastic syndrome Mikkael A Sekeres OriginalPaper Pages: 34 - 38
Farnesyltransferase inhibitors in myelodysplastic syndrome E. J. Feldman OriginalPaper Pages: 20 - 24
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good? Mikkael A. SekeresAlan List OriginalPaper Pages: 16 - 19
Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification Rami S. KomrokjiJohn M. Bennett OriginalPaper Pages: 9 - 15
